scholarly journals Roles of Translational Research in Pharmaceutical Companies: Toward Improvement of Productivity in Pharmaceutical Research & Development through Paradigm Shift

2009 ◽  
Vol 57 (3) ◽  
pp. 157-166 ◽  
Author(s):  
Makoto TANAKA
Keyword(s):  
Translational Research ◽  
Paradigm Shift ◽  
Pharmaceutical Research ◽  
Pharmaceutical Companies ◽  
Research Development

Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries

2019 ◽  
Vol 59 (1) ◽  
pp. 405-421 ◽  
Author(s):  
Marcus C. Parrish ◽  
Yuan Jin Tan ◽  
Kevin V. Grimes ◽  
Daria Mochly-Rosen
Keyword(s):  
Drug Discovery ◽  
Translational Research ◽  
Early Stage ◽  
The United States ◽  
Academic Programs ◽  
Government Policies ◽  
Pharmaceutical Companies ◽  
Financial Return ◽  
Know How ◽  
Valley Of Death

With pharmaceutical companies shrinking their research departments and exiting out of efforts related to unprofitable diseases, society has become increasingly dependent on academic institutions to perform drug discovery and early-stage translational research. Academic drug discovery and translational research programs assist in shepherding promising therapeutic opportunities through the so-called valley of death in the hope that a successful new drug will result in saved lives, improved health, economic growth, and financial return. We have interviewed directors of 16 such academic programs in the United States and found that these programs and the projects therein face numerous challenges in reaching the clinic, including limited funding, lack of know-how, and lack of a regional drug development ecosystem. If these issues can be addressed through novel industry partnerships, the revision of government policies, and expanded programs in translational education, more effective new therapies are more likely to reach patients in need.

scholarly journals Development of public financing initiatives in pharmaceutical R&D – is it the key to the future of medicine?

2021 ◽  
Vol 11 (22) ◽  
pp. 316-324
Author(s):  
Ildikó Ádám ◽  
Zoltán Kaló
Keyword(s):  
Research And Development ◽  
Public Funding ◽  
Pharmaceutical Research ◽  
Pharmaceutical Companies ◽  
The European Union ◽  
The Public ◽  
Medical Needs ◽  
The Past ◽  
Medical Need ◽  
High Prevalence

The pharmaceutical research and development process only begin if the drug holds the promise of being profitable. In the past pharmaceutical companies aimed to find solutions for common diseases with high prevalence. Meanwhile, the unmet medical need did not decrease in several therapeutic areas. Public policymakers had to encourage pharmaceutical companies to invest in research and development in areas with high unmet medical needs. Several public measures (including financing initiatives) were introduced. In this paper, we focus on the public research and development and regulatory incentives to accelerate investment. In the past decades, there has been a considerable increase in public funding in the European Union, which diverted the attention of innovators to areas with public priorities. Still, there are areas where public funding alone could not lead to a prompt solution.

Ethical Principles for Research Governance of Biobanks

2006 ◽  
Vol 3 (6) ◽  
Author(s):  
Don Chalmers
Keyword(s):  
Health Care ◽  
Clinical Trial ◽  
Large Scale ◽  
Genetic Research ◽  
Pharmaceutical Research ◽  
Epidemiological Studies ◽  
Pharmaceutical Companies ◽  
Tissue Samples ◽  
Causes Of Disease ◽  
Ethics Council

AbstractBiobanks of collected human tissue samples are rapidly expanding and becoming „essential tools in translating biomedical research into real improvements in health care”. Biobanks are rich sources for genetic research. The German National Ethics Council has noted, for example, the potential of biobanks for the identification of causes of disease and for breakthroughs in medical and pharmaceutical research. Unsurprisingly, many pharmaceutical companies operate biobank collections for research purposes and to enrol suitable clinical trial recruits so as to minimise side effects and achieve better results. Biobanks are also essential tools for conducting large-scale epidemiological studies, involving whole populations (with the neologism „epigenetic”). One commentator has noted that biobanks are invariably ”staggeringly expensive”

Sign in / Sign up

Export Citation Format

Share Document